| Document |
Document Title |
|
WO/2022/161468A1 |
The invention provides pharmaceutical compositions of berberine ursodeoxycholate (BUDCA) and methods of use thereof for the treatment primary sclerosing cholangitis, and related diseases and conditions.
|
|
WO/2022/155290A1 |
Novel Fusidic Acid (FA) based compounds that have equivalent potency against clinical isolates of Staphylococcus aureus (S. aureus) and Enterococcus faecium (E. faecium) as well as an improved resistance profile in vitro when compared to...
|
|
WO/2022/139630A1 |
The invention relates to the field of chemistry, and more particularly to a method for producing high-purity phytosterols. The present method includes dissolving a concentrate of tallow oil neutral substances in a mixed solvent consistin...
|
|
WO/2022/115710A1 |
7β-hydroxylation systems are provided, as well as methods for producing ?P-hydroxy derivatives of lithocholic acid and 3-keto-lithocholic acid from such systems. Also provided are recombinant organisms useful for the production of such ...
|
|
WO/2022/100722A1 |
A 5,6-epoxy sterol compound intermediate, and a preparation method therefor and an application thereof. The intermediate has a chemical structure represented by formula I, wherein R is selected from -CH 2OCOR 1 or -CH＝CH-CO(O)R 1, and ...
|
|
WO/2022/083809A1 |
The invention relates to brassinosteroid-derived cholestane derivatives, their use in the protection of cell damage, injury and cell death and compositions containing these derivatives. New generation of compounds possess also selective ...
|
|
WO/2022/045354A1 |
The present invention addresses the problem of providing the development of a simpler, more efficient method for producing a phytosterol starting material. The present invention is a method for producing a phytosterol starting material, ...
|
|
WO/2022/040635A1 |
Prodrugs that target the low-density lipoprotein receptor (LDLR) and that comprise acid and/or enzyme cleavable acetal- or oxybenzyloxy-linked carbonate or carbamate bonds are described. Also described are core-shell nanoparticles compri...
|
|
WO/2021/258723A1 |
Disclosed is a method for synthesizing a lithocholic acid, comprising: using 21-hydroxy-20-methylpregn-4-en-3-one (BA) as a raw material, undergoing an oxidizing reaction and a Wittig reaction, then synthesizing the lithocholic acid thro...
|
|
WO/2021/244051A1 |
The present invention provides an 11-O-mogrol oxime ether derivative and a preparation method therefor. The structural formula is as shown in formula (I). The mogrol oxime ether derivative is a product 11-O-mogrol oxime ether derivative ...
|
|
WO/2021/248049A1 |
Described herein are compounds and pharmaceutical compositions containing such compounds for the modulation of Hedgehog signaling.
|
|
WO/2021/235508A1 |
Provided is a pharmaceutical composition for treating and/or preventing fatty liver diseases, in particular, nonalcoholic fatty liver diseases, said pharmaceutical composition having excellent ACC2-selective inhibitory action without acc...
|
|
WO/2021/231646A1 |
Provided herein are methods for treating liver disorders, including non-alcoholic steatohepatitis, and symptoms and manifestations thereof, in a patient which utilize, among others, a combination treatment of an FXR agonist and a ΤΗΚ...
|
|
WO/2021/231644A1 |
Provided herein are methods for treating liver disorders, including non-alcoholic steatohepatitis, and symptoms and manifestations thereof, in a patient which utilize, among others, a combination treatment of an FXR agonist and an SSAO i...
|
|
WO/2021/222534A1 |
The present invention pertains to anti-coronaviral compounds. The disclosure includes a method for preventing and/or treating a coronavirus infection through the inhibition of a cysteine protease in a virus, particularly SARS-COV-2. Also...
|
|
WO/2021/213984A1 |
The present invention relates to a new synthesis of 7- dehydrocholesterol or itsOH-protected forms of the formula I by the reaction of a compound of formula (ll)in the presence of a solvent of formula (III), comprising the step (a) where...
|
|
WO/2021/214685A1 |
The present invention refers to a method for the preparation of a compound of formula (I).
|
|
WO/2021/213518A1 |
The present invention relates to the field of biomedicine, and specifically relates to an "LC3 binding portion-lipid droplet binding portion-conjugate" formed by means of covalently linking a structure capable of binding LC3 and a struct...
|
|
WO/2021/213988A1 |
The present invention relates to the purification of 7-dehydrocholesterol or 25-hydroxy-7-dehydrocholesterol or their OH-protected forms, respectively. It has been found that the process using organic solvent nanofiltration allows an eff...
|
|
WO/2021/200179A1 |
The present invention provides an actinic-ray-sensitive or radiation-sensitive resin composition comprising (A) a resin which increases in polarity by the action of an acid and (B) a compound which generates an acid upon irradiation with...
|
|
WO/2021/194244A1 |
The present invention relates to a novel method for preparing Inotodiol. The method differs in terms of process from existing methods for preparing Inotodiol, and produces a high yield of Inotodiol. Therefore, the method can be useful fo...
|
|
WO/2021/188778A2 |
Provided herein is a compound of Formula (I), or a pharmaceutically acceptable salt thereof, wherein R2a, R2b, R3, R 4a, R4b, R5, R6a, R6b, R11a, R11b, R15a, R15b, R16a, R16b, R18, R19, R20a, R20b, X, A, Z, q, u, r, s, t, m, and n are de...
|
|
WO/2021/153708A9 |
Provided is a novel growth inhibitor of Helicobacter pylori. This growth inhibitor of Helicobacter pylori comprises, as an active ingredient, stenone and/or a compound having a sterol skeleton other than cholesterol.
|
|
WO/2021/182111A1 |
Provided is a composition for stabilizing proteins. More specifically, the invention provides a compound represented by general formula (I). [In the formula, R represents a saturated or unsaturated hydrocarbon group; X represents a hydro...
|
|
WO/2021/167770A1 |
Disclosed are immune cell-selective small molecule compounds that modulate certain immune cell-specific receptors and enzymes, and methods of their synthesis and use to treat proliferative disorders.
|
|
WO/2021/157665A1 |
The present invention provides a hyaluronic acid derivative into which a steryl group is introduced, wherein the ratio (Mw/Mn) of the weight average molecular weight (Mw) to the number average molecular weight (Mn) of the hyaluronic acid...
|
|
WO/2021/155167A1 |
GCPII inhibitors comprising 2-(phosphonomethyl) pentanedioic acid (2-PMPA) conjugated to a bile acid and their use for treating a disease or condition associated with elevated levels of GCPII, including inflammatory bowel disease.
|
|
WO/2021/140480A1 |
It is provided a method for the preparation of 3β-arachidylamido-7α,12α-dihydroxy-5β-cholan-24-carboxyl
ic acid comprising the step of: d) reacting compound (IV) with methane sulphonyl chloride to get methyl 7α,12α-diacetyloxy-3α-...
|
|
WO/2021/120127A1 |
The present invention relates to the field of pharmaceutical chemistry, and in particular relates to a method for preparing cholesterol, a derivative and an analogue thereof. The cholesterol derivative comprises, but is not limited to, 7...
|
|
WO/2021/121239A1 |
The present invention relates to the field of pharmaceutical chemistry, and specifically to a method for preparing cholesterol, a derivative thereof, and an analog thereof. The derivative of cholesterol comprises, but is not limited to, ...
|
|
WO/2021/116935A1 |
The present invention relates to compounds of formula (I), to pharmaceutical compositions thereof and to their uses, in particular in the treatment and/or prevention of GPBAR1 mediated diseases.
|
|
WO/2021/109791A1 |
A method for synthesizing ursodeoxycholic acid, comprising: taking a plant-derived compound BA as a raw material, and synthesizing ursodeoxycholic acid by the steps of ethylene glycol or neopentyl glycol protection, oxidation, Wittig rea...
|
|
WO/2021/109883A1 |
Provided in the present invention is a method for use in preparing obeticholic acid. Specifically, the present invention prepares the compound as represented by formula (1) by employing a novel intermediate and route. The method is simpl...
|
|
WO/2021/105147A1 |
It is provided a cocrystal of a compound of formula (I) or of a compound formula (II) wherein X and Y are independently selected from -CH2- and -C(CH2)-, provided that al least one of X or Y is -CH2-; R1 is -CHCH3-Zm-Wn-(CH2)o-Tp-S, wher...
|
|
WO/2021/058648A1 |
A process for purification of phytosterols, said process comprising, a. providing a liquid mixture comprising a phytosterol, lower alcohol, wherein the lower alcohol is present in an amount of from 25 to 800% by weight, based on the amou...
|
|
WO/2021/058646A1 |
The presently claimed invention relates to a process for the production and purification of sterols from oil distillates or oil distillation residues, in particular from the latter. Specifically, the presently claimed invention relates t...
|
|
WO/2021/046678A1 |
A method for synthesising chenodeoxycholic acid and an application therefor, relating to the technical field of pharmaceutical and chemical product synthesis, and used for solving the technical problem of the high production costs of exi...
|
|
WO/2021/043845A1 |
In its first aspect, the disclosure concerns a process for providing an extract of phytosterols and stanols from tall oil pitch with the steps of (b) saponifying tall oil pitch by addition of a basic compound; (c) extracting the saponifi...
|
|
WO/2021/036998A1 |
Provided are a novel bile acid derivative for treating fatty liver disease, a pharmaceutical composition thereof, and a use in the preparation of a medicine for treating and improving diseases and symptoms mediated or caused by FXR or TG...
|
|
WO/2021/033766A1 |
The purpose of the present invention is to provide a novel lithocholic acid derivative having sufficient vitamin D3 activity. A compound represented in general formula (I), a salt thereof, or a prodrug thereof is provided. (R1 and R2 ind...
|
|
WO/2021/016954A1 |
Disclosed are a 3-acetyl-5-hydroxy-B-norcholesterol-6-(N-methyl)thiosemicarb
azone, a preparation method therefor and the use thereof, and structural formula (I) of the 3-acetyl-5-hydroxy-B-norcholesterol-6-(N-methyl)thiosemicarb
azone. ...
|
|
WO/2021/005618A1 |
The present invention discloses novel method for synthesizing vegan cholesterol and vitamin D3 from inexpensive crude phytosterol.
|
|
WO/2020/264512A1 |
Provided herein in part is a compound of Formula (I): or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising a compound of Formula I, and methods of using the compounds, e.g, in the treatment of CNS- relate...
|
|
WO/2020/252713A1 |
The present invention relates to the preparation of a hydrophobic medicinal auxiliary material and a drug-loaded fat emulsion, and in particular to a hydrophobic auxiliary material with the structural formula as shown below, wherein R is...
|
|
WO/2020/244483A1 |
Provided are novel chemical compounds in which a lipophilic moiety such as a lipid, fatty acid, polyethylene glycol or terpene is covalently attached to a non-acylated or desacylated triterpene saponin via a carboxyl group present on the...
|
|
WO/2020/240483A1 |
The present invention relates to, in part, a combination therapy of a polyhydroxylated bile acid and a famesoid X receptor agonist. The present invention also provides, in part, a pharmaceutical composition comprising a famesoid X recept...
|
|
WO/2020/243488A1 |
Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1a, R1b, R2a, R2b, R3, R4a, R4b, R5, R6a, R6b, R7a, R7a, R11a, R11b, R12a, R12b, R16a, R16b, R19, R11a, R22, RX, RY and n are defined he...
|
|
WO/2020/230159A1 |
The invention discloses an improved process for production of vitamin D3 from 7- dehydrocholesterol (7- DHC) and to a simple process for recovery unreacted 7-DHC for further reuse. The invention further describes a process for isolation ...
|
|
WO/2020/221113A1 |
Provided by the present invention is a preparation method for momordin Ib, comprising: first, mixing a plant containing a triterpene saponin derivative having the structural unit shown in formula (I) or a plant extract containing a trite...
|
|
WO/2020/218383A1 |
Development of a novel GLP-secretagogue for promoting secretion of GLP-1 is anticipated. The present invention provides a GLP-secretagogue characterized by containing 2 ppm or more of mogroside.
|
